TY - JOUR
T1 - 3D bioprinting of skin tissue
T2 - From pre-processing to final product evaluation
AU - Yan, Wei Cheng
AU - Davoodi, Pooya
AU - Vijayavenkataraman, Sanjairaj
AU - Tian, Yuan
AU - Ng, Wei Cheng
AU - Fuh, Jerry Y.H.
AU - Robinson, Kim Samirah
AU - Wang, Chi Hwa
N1 - Funding Information:
This project was supported by A*STAR and the National University of Singapore under the project/grant numbers APG2013/40A (A*STAR BMRC Strategic Positioning Fund, R279–000-487–305) and R261–509-001–646 (NUS FOE 3D Printing Initiatives).
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/7
Y1 - 2018/7
N2 - Bioprinted skin tissue has the potential for aiding drug screening, formulation development, clinical transplantation, chemical and cosmetic testing, as well as basic research. Limitations of conventional skin tissue engineering approaches have driven the development of biomimetic skin equivalent via 3D bioprinting. A key hope for bioprinting skin is the improved tissue authenticity over conventional skin equivalent construction, enabling the precise localization of multiple cell types and appendages within a construct. The printing of skin faces challenges broadly associated with general 3D bioprinting, including the selection of cell types and biomaterials, and additionally requires in vitro culture formats that allow for growth at an air-liquid interface. This paper provides a thorough review of current 3D bioprinting technologies used to engineer human skin constructs and presents the overall pipelines of designing a biomimetic artificial skin via 3D bioprinting from the design phase (i.e. pre-processing phase) through the tissue maturation phase (i.e. post-processing) and into final product evaluation for drug screening, development, and drug delivery applications.
AB - Bioprinted skin tissue has the potential for aiding drug screening, formulation development, clinical transplantation, chemical and cosmetic testing, as well as basic research. Limitations of conventional skin tissue engineering approaches have driven the development of biomimetic skin equivalent via 3D bioprinting. A key hope for bioprinting skin is the improved tissue authenticity over conventional skin equivalent construction, enabling the precise localization of multiple cell types and appendages within a construct. The printing of skin faces challenges broadly associated with general 3D bioprinting, including the selection of cell types and biomaterials, and additionally requires in vitro culture formats that allow for growth at an air-liquid interface. This paper provides a thorough review of current 3D bioprinting technologies used to engineer human skin constructs and presents the overall pipelines of designing a biomimetic artificial skin via 3D bioprinting from the design phase (i.e. pre-processing phase) through the tissue maturation phase (i.e. post-processing) and into final product evaluation for drug screening, development, and drug delivery applications.
KW - 3D bioprinting
KW - Artificial skin
KW - Skin tissue engineering
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=85050780977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050780977&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2018.07.016
DO - 10.1016/j.addr.2018.07.016
M3 - Review article
C2 - 30055210
AN - SCOPUS:85050780977
SN - 0169-409X
VL - 132
SP - 270
EP - 295
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -